Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 451,100 shares, a decline of 19.8% from the February 13th total of 562,300 shares. Currently, 63.5% of the shares of the company are short sold. Based on an average trading volume of 3,410,000 shares, the short-interest ratio is presently 0.1 days.

Conduit Pharmaceuticals Price Performance

Shares of CDT stock opened at $1.09 on Monday. Conduit Pharmaceuticals has a 1 year low of $0.98 and a 1 year high of $392.00. The firm has a fifty day moving average price of $3.46 and a 200-day moving average price of $7.86.

Institutional Investors Weigh In On Conduit Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Citadel Advisors LLC grew its position in shares of Conduit Pharmaceuticals by 177.0% during the 4th quarter. Citadel Advisors LLC now owns 526,268 shares of the company’s stock valued at $36,000 after acquiring an additional 336,278 shares during the period. Barclays PLC lifted its stake in shares of Conduit Pharmaceuticals by 6.5% during the 4th quarter. Barclays PLC now owns 892,350 shares of the company’s stock valued at $61,000 after buying an additional 54,523 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Conduit Pharmaceuticals by 36.8% during the 4th quarter. Geode Capital Management LLC now owns 584,984 shares of the company’s stock valued at $40,000 after buying an additional 157,307 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Conduit Pharmaceuticals by 5,034.0% during the 4th quarter. Rhumbline Advisers now owns 1,028,702 shares of the company’s stock valued at $71,000 after buying an additional 1,008,665 shares in the last quarter. Institutional investors own 3.29% of the company’s stock.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.